Last reviewed · How we verify

NCT06634693

Controlled Desaturation Study for TipTraQ SpO2 Performance Validation

Completed Last updated 10 October 2024
What this trial tests

trial in Hypoxia in 12 participants. Completed in 11 October 2023.

Timeline
10 October 2023
Primary endpoint
11 October 2023
11 October 2023

Quick facts

Lead sponsorPranaQ Pte. Ltd.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment12
Start date10 October 2023
Primary completion11 October 2023
Estimated completion11 October 2023
Sites1 location across United States

Conditions studied

Sponsor

PranaQ Pte. Ltd.

Who can join

Adults 18 to 50, any sex, with Hypoxia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to validate the performance of SpO2 measurement of the TipTraQ by comparing it with measurement from an artery blood sample of a healthy volunteer in a controlled desaturation study. The overall framework of the validation process followed Annex EE.2 of ISO 80601-2-61:2019.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypoxia

Currently open trials in the same condition.

Other PranaQ Pte. Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06634693.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing